Pfizer jumped 8% Friday morning, while Moderna dropped 17.8%, Regeneron 6.2% and Merck 9%.
Category: breaking-news
Pfizer Says Its Covid Pill Reduced Risk Of Hospitalization And Death By 89% In Clinical Study
The pharmaceutical giant will submit the data to the FDA to continue its application for emergency use authorization.
‘Egregiously Incorrect’: Immunologist Fauci And Eye Doctor Rand Paul Clash Over Covid Origins—Again
Dr. Fauci denied Paul’s claims that the NIH funded dangerous research in Wuhan.
Moderna Crash Wipes Out Another $24 Billion After Supply Chain Issues Dent Covid Vaccine Sales
Now trading at their lowest level in three months, Moderna shares have struggled as experts question the long-term viability of the firm’s Covid-19 vaccine sales.
Kids Ages 5-11 Are Now Eligible For Covid Vaccines—But Polls Suggest Many Parents Won’t Let Their Child Get The Shot
Polling suggests a sizable minority of parents still don’t want to vaccinate their children.
Novavax Covid-19 Vaccine Gets First Emergency Authorization In Indonesia—Here’s What You Need To Know
The shot marks the first time an older, protein-based shot has been approved to fight Covid-19 and the first vaccine Novavax has been able to bring to market in its 34-year history.
Covid Has Now Killed 5 Million People Worldwide. Six Countries Account For Most Of Those Deaths.
The Covid-19 pandemic surpassed 5 million deaths Monday, but a handful of countries make up an outsized share of the virus’ total death toll.
England On Track To Be First In World To Prescribe E-Cigarettes As Government Moves To Stamp Out Smoking
While not risk-free, e-cigarettes are less dangerous than cigarettes and can help people give up smoking, U.K. officials said.
Syringe Shortage Threatens Vaccine Efforts In Africa — Where Fewer Than 10% Of Countries Have Reached Vaccine Milestone
Just 6% of Africa’s population is fully vaccinated.
Merck Sees Up To $1 Billion In Covid Antiviral Pill Sales—It Just Needs Regulatory Approval
Merck anticipates up to $7 billion in revenue from the drug through 2022, which it says can halve the risk of hospitalization and death in high-risk patients.
